Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Polymyalgia Rheumatica article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Polymyalgia rheumatica (PMR) is an inflammatory condition of unknown cause which is characterised by severe bilateral pain and morning stiffness of the shoulder, neck and pelvic girdle. There is ongoing debate as to whether or not PMR represents a form of giant cell arteritis (GCA), or whether they are distinct conditions, as they often co-exist, they share many common features and both respond to corticosteroids. 40-50% of people with GCA have associated PMR, and around 15% of those with PMR go on to develop GCA.
- The annual incidence of the disease in the general population in the UK has been estimated as 95 per 100,000.
- PMR occurs almost exclusively in people aged above 50 and the mean age of onset is about 73.
- Lifetime risk is around 2.4% for women and 1.7% for men.
- PMR is seen mainly in people of north European ancestry, although it can occur in any ethnic group.
- Women are more frequently affected than men.
The cause of PMR is unknown. Studies suggest that both genetic and environmental factors might be important in disease pathogenesis. Familial aggregation is rare but has been described.
The presenting symptoms are nonspecific but PMR should be suspected in patients aged over 50 who have subacute to acute onset of bilateral, severe and persistent pain in the neck, shoulders and pelvic girdle. Core inclusion criteria for a diagnosis of PMR include:
- Age over 50 years and duration of symptoms more than two weeks.
- Bilateral shoulder or pelvic girdle aching, or both.
- Morning stiffness of more than 45 minutes in duration.
- Evidence of an acute-phase response (raised ESR/CRP). PMR can be diagnosed with a normal ESR and/or CRP if there is a classic clinical picture and response to steroids. These patients should be referred for specialist assessment.
The most characteristic presenting feature of PMR is bilateral shoulder pain and stiffness of acute or subacute onset with bilateral upper arm tenderness. Symptoms are at their worst on waking. The stiffness may make it difficult to get out of bed, or raise their arms sufficiently to brush their hair. There may be flu-like features at the onset, which is usually sudden, or over the course of 1-2 weeks.
Exclusion criteria are active infection, cancer or GCA. Assessment should be made clinically for GCA, as this would require an immediate high-dose steroid, whereas a diagnosis of PMR can await further investigation, and the dose of steroid will be lower. Examination should be made to exclude other differential diagnoses as well as GCA, particularly looking for lymphadenopathy (there should be none for a diagnosis of PMR), thyroid disease or involvement of other organs and systems.
- Rheumatoid arthritis (RA).
- Late-onset spondyloarthropathy, including ankylosing spondylitis, psoriatic arthritis.
- Systemic lupus erythematosus, scleroderma, Sjögren's syndrome, vasculitis.
- Dermatomyositis, polymyositis.
- Degenerative disease: osteoarthritis, spinal spondylosis.
- Rotator cuff disease, adhesive capsulitis (frozen shoulder).
- Drug-induced myalgia (eg, statins).
- Infections, including viral syndromes, osteomyelitis, infective endocarditis, tuberculosis.
- Malignancy - eg, lymphoma, leukaemia, lung cancer, myeloma, prostatic carcinoma.
- Chronic pain syndromes, fibromyalgia, depression.
- Endocrinopathy and metabolic bone disease: hyperthyroidism, hypothyroidism, hyperparathyroidism, hypoparathyroidism, osteomalacia, pseudogout with calcium pyrophosphate deposition.
Investigations are essential to support the diagnosis of PMR but also to rule out any other possible diagnosis. Investigations advised as essential by the British Society of Rheumatology (BSR) guidelines, to be done in all those with suspected PMR before starting steroid treatment, are:
- Inflammatory markers: ESR, plasma viscosity and/or CRP. Raised inflammatory markers are a characteristic laboratory finding in PMR but may be normal. CRP is more sensitive than ESR.
- Bone profile.
- Protein electrophoresis.
- Creatine kinase.
- Rheumatoid factor.
Further investigations to consider are:
- Urinary Bence Jones' protein
- Autoantibodies - anti-nuclear antibody (ANA) and anti-cyclic citrullinated peptide (anti-CCP) antibody.
- Ultrasound scans of the shoulders and/or hips are sometimes used if the diagnosis is unclear. Typical findings on ultrasound include subdeltoid bursitis and biceps tendon tenosynovitis and, less frequently, synovitis of the glenohumeral joint or trochanteric bursitis.
Consider GCA in all people with PMR. Symptoms of GCA include new headache, jaw claudication (jaw muscle pain on chewing) and visual disturbance. On examination, the temporal artery may be abnormal to palpation; biopsy of this artery usually yields characteristic findings of vascular inflammation. Such a biopsy should be considered in any patient with polymyalgic symptoms and new headache.
There may be some overlap with RA, and some people with PMR are subsequently diagnosed with RA. The presence of anti-CCP antibodies may alert the clinician to a diagnosis of early RA.
Glucocorticoids are the only known effective treatment. Non-steroidal anti-inflammatory agents are of little value for the management of this disease. There is little evidence for the efficacy of steroid-sparing agents - eg, methotrexate or anti-tumour necrosis factor agents. Methotrexate is the most commonly used corticosteroid sparing agent. Azathioprine is also used but there is no evidence for long-term beneficial outcome in either.
- Manage any residual physical or psychosocial disability caused by the disease. Patients with PMR are frequently elderly and may have mobility problems and difficulty with many aspects of daily living. Some may benefit from referral to a physiotherapist and occupational therapist for assessment.
- Screen for increased risk of adverse reaction to steroids before starting (diabetes, hypertension, history of peptic ulcer, osteoporosis, mental health history).
- Unlike GCA, urgent institution of steroid therapy is not necessary and can be delayed to allow full assessment. However, if the patient does present with symptoms suspicious of GCA then urgent institution of high-dose steroid therapy is required.
- Lack of complete response to recommended doses of prednisolone, as well as atypical clinical features (younger age, muscle weakness, peripheral joint disease, and predominance of pain with little or no stiffness), should lead to consideration of alternative diagnoses.
- Patients should be assessed for response to an initial dose of prednisolone 15 mg daily orally. A patient-reported global improvement of at least 70% within a week of commencing steroids is consistent with PMR, with normalisation of inflammatory markers in four weeks. A lesser response should prompt the search for an alternative condition.
Recommended steroid therapy regime
- Daily prednisolone 15 mg for three weeks.
- Then reduce to 12.5 mg for three weeks.
- Then reduce to 10 mg for four to six weeks.
- Then reduce by 1 mg every four to eight weeks or alternate day reductions (eg, 10/7.5 mg on alternate days).
- Tailor this to the individual according to symptoms.
- Treatment is usually required for one to two years. Maintenance dose is usually 2.5-5 mg daily. Steroids may be stopped when the patient is asymptomatic from their inflammatory symptoms.
See the person after one to three weeks to assess clinical response to steroids and adverse effects. Also review one week after each dose change and at three-monthly intervals.
At each appointment, monitor response and review:
- Symptoms: morning stiffness, proximal hip and girdle pain, disability related to PMR. Symptoms and signs suggesting an alternative diagnosis.
- Ask about symptoms of GCA (headache, visual disturbance, jaw or tongue claudication.) Remind the person to present immediately if any of these symptoms develop.
- Adverse events including weight gain, dyspepsia, osteoporotic stress fractures.
- Check blood pressure and glucose.
- Laboratory markers: CRP and ESR.
Adverse effects of treatment:
- Glucocorticoid-related adverse events are common and include osteoporosis, avascular necrosis, infections, diabetes, insufficiency fractures, steroid myopathies, hypertension, hyperlipidaemia and cataracts.
- Drug-related side-effects include hyperlipidaemia and osteoporosis. These side-effects must be monitored and measures should be taken to prevent and manage them.
- Overtreatment with corticosteroids is often the result of underlying degenerative symptoms being misinterpreted as persistent PMR, or a persistently raised ESR being attributed to underlying active disease.
Prevention and treatment of steroid-induced osteoporosis
See also the separate Osteoporosis Risk Assessment and Primary Prevention article.
- Individuals with high fracture risk - eg, aged 65 years or older or prior fragility fracture:
- Bisphosphonate with calcium and vitamin D supplementation.
- Dual-energy X-ray absorptiometry (DXA) scan is not required.
- Patients without high fracture risk:
- Calcium and vitamin D supplementation when starting steroid therapy.
- DXA scan is recommended. Bisphosphonates may be indicated if T score is 1.5 or lower.
- Individuals requiring higher initial steroid dose:
- Bisphosphonate with calcium and vitamin D supplementation (higher cumulative steroid dose is likely).
Specialist referral is recommended for:
Atypical clinical presentations:
- Patient aged under 60 years.
- Chronic onset.
- Lack of shoulder involvement.
- Lack of inflammatory stiffness.
- 'Red flag' features: prominent systemic features, weight loss, night pain, neurological signs.
- Peripheral arthritis or other features of autoimmune or muscle disease.
- Normal or very high (ESR/CRP above 100) inflammatory markers.
- Incomplete or non-response to corticosteroids.
- Ill-sustained response.
- Unable to reduce corticosteroid dose.
- Need for prolonged corticosteroid therapy (longer than two years).
- Contra-indications to corticosteroid therapy.
However, patients with a typical clinical picture and complete sustained response to treatment, and no adverse events, can be managed in primary care.
Relapse of disease
Relapse is the recurrence of symptoms of PMR or onset of GCA, and not just unexplained raised ESR or CRP. Treatment of relapse:
- Clinical features of GCA: treat as GCA (usually oral prednisolone 40-60 mg daily). See the separate Giant Cell Arteritis article.
- Clinical features of PMR: increase prednisolone to previous higher dose. Single intramuscular injection of methylprednisolone (Depo-Medrone®) 120 mg can also be used.
- Further relapses: consider introducing immunosuppression therapy (eg, methotrexate) after two relapses.
- The risk of GCA occurring while PMR is being treated is approximately 15%.
- The course and prognosis of PMR are very variable. Response to systemic corticosteroids is rapid and dramatic, usually within a few days, but treatment for 1-2 years is often required and some people may need low-dose corticosteroids for longer periods.
- Relapse is common but responds to restarting or increasing the dose of systemic corticosteroids.
- PMR is not associated with increased mortality but morbidity and mortality may occur as a result of immunosuppression or steroid side-effects.
Further reading and references
Nesher G, Breuer GS; Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam Maimonides Med J. 2016 Oct 317(4). pii: RMMJ.10262. doi: 10.5041/RMMJ.10262.
Mackie SL, Mallen CD; Polymyalgia rheumatica. BMJ. 2013 Dec 3347:f6937. doi: 10.1136/bmj.f6937.
Ameer F, McNeil J; Polymyalgia rheumatica: clinical update. Aust Fam Physician. 2014 Jun43(6):373-6.
Polymyalgia rheumatica; NICE CKS, January 2019 (UK access only)
Kermani TA, Warrington KJ; Polymyalgia rheumatica. Lancet. 2013 Jan 5381(9860):63-72. doi: 10.1016/S0140-6736(12)60680-1. Epub 2012 Oct 8.
Management of polymyalgia rheumatica; British Society for Rheumatology (November 2009)
Iagnocco A, Finucci A, Ceccarelli F, et al; Musculoskeletal ultrasound in the evaluation of Polymyalgia Rheumatica. Med Ultrason. 2015 Sep17(3):361-6. doi: 10.11152/mu.2013.2066.173.aig.
Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, et al; Medical management of polymyalgia rheumatica. Expert Opin Pharmacother. 2010 May11(7):1077-87. doi: 10.1517/14656561003724739.
Diagnosis and management of polymyalgia rheumatica; Royal College of Physicians (June 2010)